Menu

    Lawyers Aysel Korkmaz Yatkın

    Aysel Korkmaz Yatkın joined the firm in 2008 and became a partner in 2019. She specializes in intellectual property; insurance and reinsurance; dispute management and business crimes and anti-corruption practices with a special focus on patents and utility models.

    With almost 15-years of experience on patents, she has been providing consultancy on all matters related to the patent law and has been leading numerous patent actions. With a vast advisory and litigation expertise particularly with regards to protection of patent rights, Aysel Korkmaz Yatkın also represents various pharmaceutical companies before the Ministry of Health in relation to the regulatory matters and gives support to these companies on regulatory matters during the audits conducted before the Ministry of Health.

    She supervises the team in relation to strategy and policy setting issues, for comprehensive and complex mandates related to the insurance disputes and negotiates the settlement assessment. She has been providing consultancy on all matters and has been leading numerous commercial disputes with a vast advisory and litigation expertise particularly with regards to compensation actions, unfair competition claims, preliminary injunction, and enforcement of the preliminary injunctions. She has significant experience helping clients achieve positive outcomes across a variety of industries and sectors.


    Practice Areas & Work Department

    Intellectual Property

    Patent and Utility Models

    Insurance and Reinsurance

    Dispute Management

    Business Crimes and Anti-Corruption

    Employment


    Languages

    English

    Turkish


    Memberships

    International Bar Association (IBA)

    Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI), Patents Committee

    Better Justice Association


    Determination of Evidence in Disputes Over Pharmaceutical Patents

    The determination of evidence, one of the most important temporary legal protection measures regulated in Turkish law, is an institution that ensures the protection of evidence, which will assist in proving the matter in question. Considering that the adversarial trial process is adopted in Turkish civil procedure law, the significance of the rights holder being able to have the evidence that will help them prove themselves effectively determined is clear. However, in disputes relating to pharmaceutical patents, the determination of evidence institution is also a prerequisite in order to benefit from a preliminary injunction, which is another interim measure institution.
    Aysel Korkmaz Yatkın

    Lack of Regulation on Plausibility Attacks in Turkish Patent Law

    The grounds for the invalidation of a patent within the scope of Turkish Industrial Property Law No. 6769 are listed as per the numerus clausus principle. The concept of plausibility – which has been the subject of numerous evaluations, especially by the EPO, and frequently debated in academic circles in recent years – has not yet found a place within the scope of any legal regulation in Turkey. Moreover, there is no consensus on the Turkish word that meets this concept as a legal term.
    Aysel Korkmaz Yatkın

    The Danger of De Facto Abolishment of the Right to Preliminary Injunction by the Determination of Evidence in Terms of Pharmaceutical Patents

    Determination of evidence, which is one of the most important temporary legal protection measures regulated in our law, is an institution that ensures the protection of evidence that will assist the proving of the matter. Considering that the adversarial trial process is adopted in our civil procedure law, the significance of the right holder being able to have the evidence which will help them prove their rightness effectively determined, is clear. However, as will be explained below, in disputes regarding pharmaceutical patents, the determination of evidence institution is also a prerequisite for benefiting from the preliminary injunction, which is another interim measure institution.
    Aysel Korkmaz Yatkın